SA-ANP(SA-ANP) - 药物靶点：Aldosterone_在研适应症：难治性高血压，慢性肾病，射血分数保留型心力衰竭_专利_临床

概要

基本信息

药物类型

生物药

别名

mANP

靶点

Aldosterone

作用机制

醛固酮拮抗剂

治疗领域

心血管疾病泌尿生殖系统疾病

在研适应症

难治性高血压慢性肾病射血分数保留型心力衰竭

非在研适应症-

原研机构

Mayo Clinic

在研机构

Mayo Clinic

非在研机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

4

项与 SA-ANP 相关的临床试验

NCT06343298 / Recruiting临床2期

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE TITRATION, MULTI-CENTER STUDY to EVALUATE the SAFETY and EFFICACY of SUBCUTANEOUS MANP WHEN ADMINISTERED ONCE DAILY for 42 DAYS in PARTICIPANTS with DIFFICULT to CONTROL HYPERTENSION/RESISTANT HYPERTENSION

This is a Phase 2 dose-titration study designed to evaluate the safety and efficacy of MANP subcutaneous injection compared to placebo in reducing baseline daytime systolic blood pressure (SBP), derived from 24-hour ambulatory blood pressure monitoring (ABPM), in subjects with hypertension who are taking 3 or more antihypertensive medications with different mechanisms of action.

开始日期2024-11-01

申办/合作机构

E-Star BioTech, LLC

[+3]

NCT05279742 / Enrolling by invitation临床1/2期IIT

Enhancing the Natriuretic Peptide System in HFpEF: a Randomized Double-Blind Placebo-Controlled Triple Crossover Study

The purpose of this study is to look at the differences in how individuals with heart failure with preserved ejection fraction in the presence of chronic kidney disease (HFpEF-CKD) and exercise induced dyspnea without objective findings of fluid retention (HFpEF-EI) bodies function using drugs Sacubatril/Valsartan (Entresto) and MANP.

开始日期2022-11-04

申办/合作机构

Mayo Clinic

NCT05247528 / Completed临床1期

A Phase 1B, Multiple Ascending Dose Trial Examining The Safety And Tolerability Of Subcutaneous MANP In Difficult To Control/Resistant Hypertensive Subjects

A randomized, double-blind, placebo-controlled multiple ascending dose study in hypertensive subjects on stable doses of at least three hypertensive drugs for at least 6 weeks prior to Screening. The study will consist of screening, PK-unit admittance, and safety follow up periods.
Subjects will be randomized at a 6:2 ratio of either MANP or placebo and will be stratified by race in each dosage cohort. The entire first Cohort will be given the lowest dosage with subsequent cohorts progressing sequentially to the higher doses depending on safety and tolerability of the previous cohort.
Endpoints not related to the safety reviews will be analyzed after the last patient last visit (LPLV).

开始日期2021-12-20

申办/合作机构

E-Star BioTech, LLC

[+2]

100 项与 SA-ANP 相关的临床结果

登录后查看更多信息

100 项与 SA-ANP 相关的转化医学

登录后查看更多信息

100 项与 SA-ANP 相关的专利（医药）

登录后查看更多信息

54

项与 SA-ANP 相关的文献（医药）

2024-12-01·Regenerative Therapy

Multifunctional type lll recombinant human collagen incorporated sodium alginate hydrogel with sustained release of extra cellular vehicles for wound healing multimodal therapy in diabetic mice

Article

作者: Jia, Yao ; Yan, Xin ; Zhang, Yue ; Zhang, Baolin ; Han, Yaxi ; Li, Lei

The effective promotion of wound healing poses a substantial challenge for clinical treatment. Despite evidence supporting the role of extracellular vesicles (EVs) in this process, their therapeutic potential is currently restrict by challenges in targeting and maintaining them. The manufacturing process for rhCol III, or recombinant human collagen III, is stable, and the rejection rate is low. We used a cross-linking method to prepare a rhCol III incorporated sodium alginate (SA) hydrogel, which enabled to accomplish an EV sustained release that was site-specific. Cell viability through MTT assay, proliferation and ROS generation were performed with MC3T3-E1cell lines. In addition, diabetic wounds are characterised by an environment of hyper-inflammation and elevated oxidative stress. The rhCol III/SA-EVs hydrogel, which is a delivery vehicle with anti-inflammatory and antioxidant characteristics, promotes wound healing in this setting. The In vivo effectiveness of the created wound dressing on a diabetic wound model was examined in this study. After 21 days of treatment, the wound dressing significantly (p < 0.05) expedited wound healing compared to the control group, and wound closure was approximately 95% without any negative systemic reactions.

2024-04-01·Colloids and Surfaces B: Biointerfaces

The investigation on sialic acid-modified pectin nanoparticles loaded with oxymatrine for orally targeting and inhibiting the of ulcerative colitis

Article

作者: Fan, Mengyao ; Sun, Changshan ; Zhao, Chunying ; Yang, Xin ; Sun, Tongtong ; Jiang, Tongying ; Tian, Linan

The aim of the study was to develop an oral targeting drug delivery system (OTDDS) of oxymatrine (OMT) to effectively treat ulcerative colitis (UC). The OTDDS of OMT (OMT/SA-NPs) was constructed with OMT, pectin, Ca²⁺, chitosan (CS) and sialic acid (SA). The obtained particles were characterized in terms of particle size, zeta potential, morphology, drug loading, encapsulation efficiency, drug release and stability. The average size of OMT/SA-NPs was 255.0 nm with a zeta potential of -12.4 mV. The loading content and encapsulation efficiency of OMT/SA-NPs were 14.65% and 84.83%, respectively. The particle size of OMT/SA-NPs changed slightly in the gastrointestinal tract. The nanoparticles can delivery most of the drug to the colon region. In vitro cell experiments showed that the SA-NPs had excellent biocompatibility and anti-inflammation, and the uptake of SA-NPs by RAW 264.7 cells was time and concentration-dependent. The conjugated SA can help the internalization of NPs into target cells. In vivo experiments showed that OMT/SA-NPs had a superior anti-inflammation effect and the effect of reducing UC, which was attributed to the delivery most of OMT to the colonic lumen, the specific targeting and retention in colitis site and the combined anti-inflammation of OMT and NPs.

2024-02-01·Colloids and Surfaces B: Biointerfaces

APTES-mediated Cu2(OH)3(NO3) nanomaterials on the surface of silicone catheters for abscess

Article

作者: Wu, Yayun ; Fu, Wanyue ; Jiang, Yechun ; Liu, Lin ; Shao, Min ; Chu, Zhaoyou ; Ye, Haoming ; Qian, Haisheng ; Li, Jun ; Fang, Ming ; Liu, Nian

Metal-based nanomaterials have remarkable bactericidal effects; however, their toxicity cannot be disregarded. To address this concern, we developed a simple synthesis route for antibacterial catheters using metal-based nanomaterials to reduce toxicity while harnessing their excellent bactericidal properties. The grafting agent (3-aminopropyl)triethoxysilane (APTES) forms -NH₂ groups on the catheter surface, onto which copper ions form a nanomaterial complex known as Cu₂(OH)₃(NO₃) (defined as SA-Cu). The synthesized SA-Cu exhibited outstanding contact antibacterial effects, as observed through scanning electron microscopy (SEM), which revealed cell membrane crumbing and bacterial rupture on the catheter surface. Furthermore, SA-Cu exhibited excellent biosafety characteristics, as evidenced by the cell counting kit-8 (CCK-8) assay, which showed no significant cytotoxicity. SA-Cu demonstrated sustained antimicrobial capacity, with in vivo experiments demonstrating over 99% bactericidal efficacy against methicillin-resistant Staphylococcus aureus (MRSA) for two weeks. The transcriptome sequencing results suggested that SA-Cu may exert its bactericidal effects by interfering with histidine and purine metabolism in MRSA. This study presents a straightforward method for synthesizing antimicrobial silicone catheters containing copper nanomaterials using copper ions.

100 项与 SA-ANP 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
难治性高血压	临床2期	美国	Mayo Clinic	2024-11-01
慢性肾病	临床2期	美国	Mayo Clinic	2022-11-04
射血分数保留型心力衰竭	临床2期	美国	Mayo Clinic	2022-11-04

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


phase 1B clinical trial (ESC2024)	临床1期	难治性高血压	36	MANP	遞醖觸淵膚繭齋構鹽繭(選餘鏇鏇窪淵積餘積鬱) = There were no reported drug related serious adverse events 選選襯製遞憲獵夢襯窪 (壓鹹醖餘衊網鹹積餘簾 ) 更多	积极	2024-08-30
				Placebo
NCT03781739 (ESC2023)	临床1期	代谢综合征 \| 高血压	22	MANP	壓醖糧鹽夢憲願觸憲窪(獵觸壓鑰餘窪鬱鑰鹽醖) = 膚獵願糧憲築蓋遞積壓鏇廠壓鹹蓋網簾網遞憲 (網遞鏇鹹積憲衊觸憲淵 ) 更多	-	2023-08-26
ESC2016	临床1期	高血压	-	ZD100	窪襯網積積範築餘廠構(壓餘艱廠淵願網餘網製) = 遞襯觸網鏇壓淵壓網繭網獵艱簾衊鹽襯願壓糧 (願鬱鹽窪鏇衊願網鏇襯 ) 更多	-	2016-08-28
				Placebo	襯窪衊願齋鏇範鏇鏇觸(積襯壓簾鬱鏇獵築築淵) = 製網簾鏇窪範淵膚憲願廠衊膚廠顧糧構鬱製選 (糧膚艱糧顧夢窪膚窪鑰 ) 更多